Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-rhPSMA-7.3
- Development stage
- Unknown
- Lead developer
- Blue Earth Therapeutics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-rhPSMA-7.3 is a radiohybrid (rh) prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical developed for the treatment of prostate cancer. It consists of the rhPSMA-7.3 ligand, a small molecule peptidomimetic, labeled with the beta-emitting radioisotope Lutetium-177. The radiohybrid technology is unique in that it allows the same chemical entity to be labeled with either Fluorine-18 for PET imaging or radiometals like Lutetium-177 for therapy, ensuring identical biological behavior across diagnostic and therapeutic applications. 177Lu-rhPSMA-7.3 binds with high affinity to PSMA, a protein highly expressed on the surface of prostate cancer cells. Once bound and internalized, the Lutetium-177 isotope emits beta particles that cause lethal DNA damage to the tumor cells. Clinical data suggests it offers high tumor uptake and a favorable therapeutic index, potentially allowing for effective treatment with lower injected activities compared to other PSMA-targeted agents.
- Other names
- Lutetium Lu 177 rhPSMA-7.3177Lu-radiohybrid PSMA-7.3Lutetium (177Lu) rhPSMA-7.3
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-rhPSMA-7.3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-rhPSMA-7.3.